Study of NUEDEXTA in the Treatment of Pseudobulbar Affect (PBA)
This is a 12-week study that will assess the safety and effectiveness of NUEDEXTA (Dextromethorphan 20mg/Quinidine10mg) in people who have Pseudobulbar Affect (PBA). PBA is a medical condition that causes sudden and involuntary bouts of crying or laughing in people with certain neurologic conditions or brain injuries. NUEDEXTA is currently FDA approved.
Location: Baylor University Medical Center
IRB Number: 013-161
Facility Name: Multiple Sclerosis Treatment Center of Dallas
Facility Street Address: 3600 Gaston Ave., Wadley Tower Suite 1155
City: Dallas, TX Zip Code: 75246
Lead Principal Investigator: Dr. Chaouki Khoury
Clinical Study Identifier | TX138958 |
---|---|
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.